The United States market has shown a robust performance, climbing 5.5% in the last 7 days and up 21% over the past year, with earnings expected to grow significantly in the coming years. In such a vibrant market, identifying stocks that combine financial strength with growth potential is key to uncovering valuable opportunities. Although 'penny stock' might seem like an outdated term, it still points to smaller or newer companies that can offer substantial returns when backed by solid fundamentals; this article highlights three promising options worth considering.

We'll examine a selection from our screener results.

1stdibs.Com (DIBS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: 1stdibs.Com, Inc. operates a global online marketplace specializing in luxury design products and has a market capitalization of approximately $146.90 million.

Operations: 1stdibs.Com, Inc. does not report distinct revenue segments.

Market Cap: $146.9M

1stdibs.Com, Inc. has shown resilience in the penny stock space with a market cap of approximately US$146.90 million and recent sales growth to US$23.32 million in Q2 2026, up from US$22.14 million a year ago. Despite being unprofitable, the company has reduced its net loss significantly over the past year and maintains a strong cash position with short-term assets exceeding liabilities by a substantial margin. The absence of debt further strengthens its financial footing, while inclusion in multiple Russell indices may enhance visibility among investors seeking value opportunities within small-cap stocks.

Health Catalyst (HCAT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Health Catalyst, Inc. offers data and analytics technology and services to healthcare organizations in the United States, with a market cap of approximately $168.48 million.

Operations: The company's revenue is generated from two main segments: Technology, which accounts for $206.26 million, and Professional Services, contributing $96.22 million.

Market Cap: $168.48M

Health Catalyst, Inc. operates within the penny stock domain with a market cap of US$168.48 million and generates revenue from its Technology and Professional Services segments. Despite being unprofitable, it has managed to reduce losses over the past five years by 1.1% annually and maintains a sufficient cash runway for over three years based on current free cash flow. The company's short-term assets surpass both short-term and long-term liabilities, providing some financial stability; however, recent exclusion from multiple Russell indices could impact investor visibility negatively while its high volatility remains a concern for potential investors seeking stability in small-cap stocks.

Pulmonx (LUNG)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Pulmonx Corporation is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, with a market cap of $87.01 million.

Operations: The company generates revenue from its Medical Products segment, which totaled $87.44 million.

Market Cap: $87.01M

Pulmonx Corporation, with a market cap of US$87.01 million, has faced challenges as an unprofitable entity with increasing losses over the past five years. Despite generating US$22.76 million in sales for Q2 2026, its net loss stood at US$10.08 million, showing some improvement from the previous year. The company maintains a strong cash position relative to its debt and has not diluted shareholders recently; however, it was removed from several Russell indices, which may affect investor visibility and sentiment. Pulmonx's experienced management and board offer stability amid high share price volatility in the penny stock landscape.

Summing It All Up

• Click this link to deep-dive into the 327 companies within our US Penny Stocks screener.
• Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.